View clinical trials related to Lipid Metabolism Disorders.
Filter by:This study is being performed to reduce unwanted fat, in various body areas, using a new applicator and control unit for Zeltiq.
The clinical protocol of the clinical testing of this device: 1. Objective of the test: To verify the functions and efficiency of devices. 2. Test methods and procedures: Comparison Test. 3. DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D. 4. Comparison device: Transtek Glass Body Analyzer, GBF-950 (Predicate Device). 5. Study endpoints: Transtek devices and the predicate device are substantial equivalence. 6. Statistical methodology used: Description of statistical methods. 7. Result: Efficiencies of Transtek devices and predicate device are in the same level.
This Phase 1 study has been designed to evaluate the absolute bioavailability of PF-04950615 (RN316) in subjects with hypercholesterolemia who are not currently on lipid-lowering therapy.
The goal of this project is to determine whether prompting the recipient of a health reminder mailing to scratch off targeted area.
Evidence exists that EPA (eicosapentaenoic acid or C20:5n-3) supplementation can reduce the risk for coronary heart disease. EPA can be synthesized from α-linolenic acid (ALA or C18:3n-3), but conversion is low. It has been suggested that the rate-limiting step for this conversion is the Δ6-desaturation of ALA into stearidonic acid (SDA or C18:4n-3). Thus, providing oils rich in SDA may increase the endogenous synthesis of EPA. This may subsequently lower serum triacylglycerol concentrations, an effect frequently observed after EPA supplementation, especially in people with increased triacylglycerol levels. The objective is to study the effects of echium oil, rich in SDA on serum triacylglycerol concentrations in healthy overweight and slightly obese men and women. The minor objective is to study the effects of echium oil on the omega-3 index, which is negatively related to cardiovascular risk and defined as the proportion of EPA and DHA in red blood cells.
The goal of this project is to determine whether prompting the recipient of a health reminder mailing to ask his or her 4-9 year-old child to color on the reminder could increase engagement with the targeted health behavior
The objective of this study is to evaluate the effect of omega 3 fatty acid on neurological recovery, lipid profile and Antioxidant system in patients with spinal cord injury. One hundred spinal cord injured patients who come to clinic of spinal injury repair research center selected. Then the patients will receive two supplements capsules of omega 3 (600 mg) in the intervention group and placebo in the control group. Primary outcome measures are professionals evaluation of neurological function by using : - ASIA scale for sensory and motor function - FIM scale for Functional potential - FAM - SF_36 for quality of life Lipid profile and Antioxidant profile evaluation by using: - FBS - 2hpp - Insulin - LDL - Total cHOL - TG - HDL - Leptin Adiponectin -Calcium- - 25OHD - PTH,LH, FSH, Prolactin,Testosterone in males Bone markers by serum levels of :Osteocalcin-Osteoprotegrin_Bone Specified ALP- CTX - RANKL - BMD
The clinical protocol of the clinical testing of this device: 1. Objective of the test: To verify the functions and efficiency of devices. 2. Test methods and procedures: Comparison Test. 3. DUT: Transtek Glass Body Analyzer, Model: GBF-830, GBF-835, GBF-950, and SA-15. 4. Comparison device: Scaleman Body Fat Scales, FS-148BW1 (Predicate Device). 5. Study endpoints: Transtek devices and the predicate device are substantial equivalence. 6. Statistical methodology used: Description of statistical methods. 7. Result: Efficiencies of Transtek devices and predicate device are in the same level.
The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.
The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.